EndyMed Ltd.

www.endymed.com

Formerly AppliSonix

High-Tech Company
Public Company

(TASE: ENDY)

Graduated from: Maayan Ventures

TECH VERTICALS

Aesthetics, Healthtech, Life Sciences, Medical Devices, MedTech, Skin Care

General Data

Sector	Medical Devices
Company Stage:	Revenue Growth
Established	2003
Number of Employees	50
Employees in Israel	35
Reg. Number:	abCDe

DESCRIPTION

EndyMed Group offers energy based medical aesthetic treatment systems for professional and consumer markets.

TECHNOLOGY

3DEEP™ is a highly effective solution for nonablative and fractional tightening and contouring treatments for the face, neck and body, acne scar and stretchmark treatment and cellulite reduction and RF Microneedling treatments.

3DEEP™ proprietary multi-source, phase controlled RF technology successfully manipulates the interaction between multiple RF energy fields to achieve the desired 3-dimensional thermal pattern in the target area. 3DEEP™ uses an array of several electrodes and a sophisticated algorithm that manipulates the phase of current flowing between each pair of electrodes. The multiple electrical fields created repel each other, leading to the ideal combination of energy directed to a deeper skin layer. The repelling forces between adjacent electromagnetic fields drive energy vertically into the target tissue, reducing the amount of energy flowing through skin surface and alleviating the need for cooling.

Products and Phases

Product	Phase
EndyMed PRO	FDA Approved CE Approved Approved for marketing in: North America, EMEA, APAC
The EndyMed PRO, powered by unique, FDA cleared 3DEEP RF technology, offers innovative and effective aesthetic solutions for non-surgical lifting, tightening, contouring, skin resurfacing and RF Microneedling for the face, neck and body. The product is an all-in-one treatment platform that is flexible and upgradeable.
EndyMed PURE 2.0	FDA Approved CE Approved Approved for marketing in: North America, EMEA, APAC
The PURE+ 2.0, the latest advance in the evolution of RF treatment systems, is powered by unique, FDA cleared 3DEEP RF technology, offers superior professional skin tightening, body contouring, RF Microneedling and Fractional Skin Resurfacing, all in one easy to use, powerful, compact and flexible treatment platform.
Intensif	FDA Approved CE Approved Approved for marketing in: North America, EMEA, APAC
The Intensif by ENDYMED is the first FDA cleared non-insulated motorized Microneedle RF Technology in the market Powered by ENDYMED's unique 3DEEP™ RF technology, the Intensif stands out amongst other microneedle technologies with its exclusive, smooth and fast operating mode.
FSR Applicator	FDA Approved CE Approved Approved for marketing in: North America, EMEA, APAC
Specially designed for fractional skin resurfacing and the treatment of skin roughness, hyperpigmentation, wrinkles and scars on both facial and body areas. 3DEEP® FSR, uniquely employs 112 tiny electrodes enabling simultaneous fractional micro-ablation of the epidermis, together with volumetric heating of 100% of the dermis.
Focused RF	FDA Approved CE Approved Approved for marketing in: North America, EMEA, APAC
Designed by experts in dermatology and RF technology, these focused RF applicators are designed to deliver exceptional skin treatments across a range of areas.
NEWA	FDA Approved OTC
NEWA harnesses the power of 3DEEP RF technology to deliver skin tightening and wrinkle reduction results in the comfort of your home. NEWA can also be used to maintain patient results in between ENDYMED treatments.

ESTIMATED ANNUAL SALES

Year	Amount
2020	500
2019	490
2018	480
2017	470
2016	460
2015	450
2014	440

	TARGET MARKETS
	Dermatologists, Beauty Parlors, Cosmeticians, Distributors, Consumer market.

	BUSINESS MODEL
	B2C

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
96D77FD8-1F7A-E111-AC59-00155D32A403		EndyMed Ltd.
10D957F6-1F7A-E111-AC59-00155D32A403	Subsidiary	CureLight Medical Ltd.	EndyMed Ltd.	Acquired/Merged
178A95C6-1F7A-E111-AC59-00155D32A403	Subsidiary	EndyMed Medical Ltd.	EndyMed Ltd.	Acquired/Merged

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm

REMARKS

Date	Remark
02/01/2012	On January 2012 AppliSonix acquired EndyMed Medical and on January 2013 changed its name to EndyMed Ltd. Most of its product development and sales is being carried out by its fully owned subsidiary, Endymed Medical.

CONTACT INFO

Expand / Collapse All

Main Address: Caesarea, Israel

Address	12 Leshem St., North Industrial Park
POB	3582
City	Caesarea
Country	Israel
Zip	3088900

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Freehold, United States

Address	4400 Route 9 South Freehold, Suite #1000
City	Freehold
State/Province	NJ
Country	United States
Zip	07728

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Yossi Bar-On	CEO	Ayana Pharma (CFO)
Mr. Erez Keinan	CFO	Allevetix (CFO)
Ms. Sima Witman	VP, R&D
Mr. Amir Meir Ganon	VP, International Sales
Mr. Asaf Nachmanovich	VP, Operations
Mr. Amir Barzilay	Co-Founder
Mr. Alon Goren	Co-Founder
Mr. Assaf Guterman	Co-Founder	ClearCut (VP, R&D)
Dr. Yoram Harth	Co-Founder
Mr. Daniel Lischinsky	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	CEO, OHMK (Tianjin) Medical Technology
abC Defghij	Board Member	OHMK (Tianjin) Medical Technology
abC Defghij	Board Member	OHMK (Tianjin) Medical Technology
abC Defghij	Board Member	OHMK (Tianjin) Medical Technology
abC Defghij	Board Member	CEO, SinoMedIs

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Jan. 28, 2007	IPO	TASE	abCDe	abCDe	Including shares and convertible debentures

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

May. 27, 2014

Initial Revenues

abCDe

Sold 29% of its shares to OHMK Medical Technology of Hong Kong, which is owned by Beijing Mansimei Medical Technology, EndyMed's distributor in China. Fully diluted, the Chinese company holds about 37% in the company.

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Other	abCDe	Holds 37% in the company.

Other

Jan. 03, 2012

abCDe

PIPE

Oct. 25, 2009

Initial Revenues

abCDe

First Round

Jan. 16, 2006

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe	Holds 5% of the company; Led the round
abC Defghij	Investment Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Incubator	abCDe	Held 17.5% of the company. Holdings sold.
abC Defghij	Other	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Dec. 21, 2009

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe	R&D grant ($0.29m)

R&D Grant

Dec. 01, 2003

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

	Acquisitions made by EndyMed

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Medica...	Jan. 02, 2012	abCDe
abC Defghij	Medica...	Aug. 25, 2008	abCDe

Last Updated:	abCDe
IVC Number:	abCDe